Page last updated: 2024-10-31

nafamostat and Dengue

nafamostat has been researched along with Dengue in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Dengue: An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rathore, AP1
Mantri, CK1
Aman, SA1
Syenina, A1
Ooi, J1
Jagaraj, CJ1
Goh, CC1
Tissera, H1
Wilder-Smith, A1
Ng, LG1
Gubler, DJ1
St John, AL1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial[NCT04673422]Phase 2/Phase 3358 participants (Actual)Interventional2021-01-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for nafamostat and Dengue

ArticleYear
Dengue virus-elicited tryptase induces endothelial permeability and shock.
    The Journal of clinical investigation, 2019, 07-02, Volume: 129, Issue:10

    Topics: Animals; Benzamidines; Capillary Permeability; Cell Line; Dengue; Dengue Virus; Endothelium, Vascula

2019